These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34656289)

  • 1. Antibody dependent enhancement: Unavoidable problems in vaccine development.
    Xu L; Ma Z; Li Y; Pang Z; Xiao S
    Adv Immunol; 2021; 151():99-133. PubMed ID: 34656289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
    Ricke DO
    Front Immunol; 2021; 12():640093. PubMed ID: 33717193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
    Karthik K; Senthilkumar TMA; Udhayavel S; Raj GD
    Hum Vaccin Immunother; 2020 Dec; 16(12):3055-3060. PubMed ID: 32845733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
    Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
    Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].
    Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV
    Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies.
    Ziganshina MM; Shilova NV; Khalturina EO; Dolgushina NV; V Borisevich S; Yarotskaya EL; Bovin NV; Sukhikh GT
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.
    Coish JM; MacNeil AJ
    Microbes Infect; 2020 Oct; 22(9):405-406. PubMed ID: 32590062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
    Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
    Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF
    Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Dependent Enhancement of SARS-CoV-2 Infection in the Era of Rapid Vaccine Development.
    Al Dossary R
    Med Arch; 2022 Oct; 76(5):383-386. PubMed ID: 36545460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccines: Should We Fear ADE?
    Halstead SB; Katzelnick L
    J Infect Dis; 2020 Nov; 222(12):1946-1950. PubMed ID: 32785649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.
    Thomas S; Smatti MK; Ouhtit A; Cyprian FS; Almaslamani MA; Thani AA; Yassine HM
    Mol Immunol; 2022 Dec; 152():172-182. PubMed ID: 36371813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection.
    Farouq MAH; Acevedo R; Ferro VA; Mulheran PA; Al Qaraghuli MM
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?
    Zanella I; Degli Antoni M; Marchese V; Castelli F; Quiros-Roldan E
    Int Immunopharmacol; 2022 Sep; 110():108943. PubMed ID: 35753123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction.
    Wang S; Wang J; Yu X; Jiang W; Chen S; Wang R; Wang M; Jiao S; Yang Y; Wang W; Chen H; Chen B; Gu C; Liu C; Wang A; Wang M; Li G; Guo C; Liu D; Zhang J; Zhang M; Wang L; Gui X
    Commun Biol; 2022 Mar; 5(1):262. PubMed ID: 35332252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages.
    Maemura T; Kuroda M; Armbrust T; Yamayoshi S; Halfmann PJ; Kawaoka Y
    mBio; 2021 Oct; 12(5):e0198721. PubMed ID: 34579572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19.
    Boldova AE; Korobkin JD; Nechipurenko YD; Sveshnikova AN
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232664
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection
    Luan N; Li T; Wang Y; Cao H; Yin X; Lin K; Liu C
    Front Immunol; 2022; 13():882856. PubMed ID: 35464483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.